Monique Hinchcliff, MD
Rheumatology · North Haven, CTNPI 1811106883
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,645 of the $20,988 with a category attached, or 60.2%. 4 manufacturers reported payments, led by Merck at 32.1% of the total. Reporting peaked in 2024 at $12,147 and has fallen 78.4% since, to $2,628 in 2025.
Across 46 payments — averaging $456.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$7K
- Boehringer Ingelheim$7K
- AbbVie$6K
- AstraZeneca$2K
Across 138 payments — averaging $6249.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$450K
- Kadmon Corporation LLC$107K
- AstraZeneca$93K
- Boehringer Ingelheim$70K
- Pfizer$46K
- Amgen$33K
- plus $64K from 3 others
What the payments were for
- Consulting fees$12,64560%
- Speaking & faculty fees$3,60917%
- Travel & lodging$3,17515%
- Food & beverage$1,5587%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $6,733 |
| Boehringer Ingelheim | 9 | $6,659 |
| AbbVie | 10 | $5,796 |
| AstraZeneca | 17 | $1,800 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,988 in reported general payments places this provider in the 85th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActemraTocilizumab | 12 | $56,527 |
| Actemra ActpenTocilizumab | 12 | $37,404 |
| Sildenafil Citrate | 26 | $16,193 |
| Mycophenolate Mofetil | 67 | $14,476 |
| Hydroxychloroquine Sulfate | 57 | $1,538 |
| MethotrexateMethotrexate Sodium | 37 | $463 |
| Omeprazole | 23 | $436 |
| Pilocarpine Hcl | 12 | $359 |
| Meloxicam | 31 | $235 |
| Nifedipine ErNifedipine | 21 | $197 |
| Prednisone | 28 | $184 |
| Losartan Potassium | 15 | $153 |
| Pantoprazole Sodium | 13 | $115 |
| Amlodipine Besylate | 20 | $115 |
| Gabapentin | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in North Haven
- Fotios KoumpourasNorth Haven$314K
- Kenneth MillerDanbury$873K
- Robert SchoenGuilford$638K
- Bret SohnStamford$447K
- James SeiboldFarmington$300K
- Michael SpiegelDanbury$215K
- John MagaldiTorrington$157K
- Archana SharmaBristol$98K
- Richard RoseffDanbury$84K
- Beth ValashinasOrange$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.